Latham & Watkins represented Rhythm Pharmaceuticals, Inc. in the transaction, while Morgan, Lewis & Bockius acted as legal advisor to HealthCare Royalty. Rhythm Pharmaceuticals, Inc. (Nasdaq:...
Rhythm Pharmaceuticals’ $100 Million Revenue Interest Financing Agreement With HealthCare Royalty Partners
Zentalis Pharmaceuticals’ $200.2 Million Common Stock Offering
Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting...
Lulu’s Fashion Lounge Holdings’ $92 Million Initial Public Offering
Latham & Watkins represented Lulu’s in the offering while Cooley advised the underwriters. Lulu’s Fashion Lounge Holdings, Inc., a customer driven, digitally native women’s fashion brand, has...
The Vita Coco Company’s $173 Million Initial Public Offering
Latham & Watkins represented The Vita Coco Company, Inc. in the offering. The Vita Coco Company, Inc., a leading platform of high-growth better-for-you brands formerly known as...